You are here

FDA Approves Allergic Rhinitis Medication for Use in Pregnant Women

NEW YORK, Aug. 26 /PRNewswire/ -- The FDA has just approved an allergic rhinitis medication for use in women who are pregnant, good news for the more than 6 million pregnant women who have nasal allergies. The medication, Rhinocort Aqua, is the first and only intranasal treatment for allergic rhinitis to receive the FDA's category B rating for pregnancy, which means that the medication is an appropriate option for pregnant women with nasal allergies.

The approval was based on evidence that the medication did not cause an increased risk of birth defects. All other medications in the class approved by the FDA for the treatment of allergic rhinitis are rated Pregnancy Category C. The achievement of a Category B rating indicates that adequate studies in pregnant women have demonstrated that there is no evidence of risk to the fetus during the first trimester of pregnancy and in later trimesters. This may give physicians greater confidence in prescribing a particular medication for women of child-bearing age or during pregnancy.

Pregnant women are often warned to limit medications. For those that suffer from nasal allergies, this can lead to an uncomfortable nine months. During pregnancy allergy symptoms may become worse and combined with what's called stuffy nose of pregnancy women can be miserable.

For more information about nasal allergies and Rhinocort Aqua, please visit www.categoryb.com, or call 800-236-9933.

Source: AstraZeneca

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut